These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35900204)
1. Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials. Zhao D; Zeng LF; Liang GH; Pan JK; Luo MH; Han YH; Liu J; Yang WY EFORT Open Rev; 2022 Jul; 7(7):470-480. PubMed ID: 35900204 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Anti-Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis. Gao Y; Hu Z; Huang Y; Liu W; Ren C Orthop J Sports Med; 2022 Apr; 10(4):23259671221088590. PubMed ID: 35494494 [TBL] [Abstract][Full Text] [Related]
3. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials. Zhao D; Luo MH; Pan JK; Zeng LF; Liang GH; Han YH; Liu J; Yang WY Ther Adv Musculoskelet Dis; 2022; 14():1759720X211067639. PubMed ID: 35069811 [TBL] [Abstract][Full Text] [Related]
4. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461 [TBL] [Abstract][Full Text] [Related]
6. The Effectiveness of Anti-Nerve Growth Factor Monoclonal Antibodies in the Management of Pain in Osteoarthritis of the Hip and Knee: A PRISMA Systematic Review and Meta-Analysis. Seah KTM; Rammanohar J; Sutton J; To K; Khan WS Pain Med; 2021 May; 22(5):1185-1204. PubMed ID: 33616179 [TBL] [Abstract][Full Text] [Related]
7. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Cao Z; Zhou J; Long Z; Li Y; Sun J; Luo Y; Wang W Aging (Albany NY); 2020 Dec; 13(1):1051-1070. PubMed ID: 33293475 [TBL] [Abstract][Full Text] [Related]
8. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Schnitzer TJ; Marks JA Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial. Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials. Fan ZR; Ma JX; Wang Y; Chen HT; Lang S; Ma XL Clin Rheumatol; 2021 Jun; 40(6):2155-2165. PubMed ID: 33159281 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials. Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979 [TBL] [Abstract][Full Text] [Related]
12. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695 [TBL] [Abstract][Full Text] [Related]
14. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Smith SR; Deshpande BR; Collins JE; Katz JN; Losina E Osteoarthritis Cartilage; 2016 Jun; 24(6):962-72. PubMed ID: 26844640 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Hale M; Tudor IC; Khanna S; Thipphawong J Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906 [TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. Tive L; Bello AE; Radin D; Schnitzer TJ; Nguyen H; Brown MT; West CR J Pain Res; 2019; 12():975-995. PubMed ID: 30936738 [TBL] [Abstract][Full Text] [Related]
17. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials. Yu Y; Lu ST; Sun JP; Zhou W Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study. Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J Arthritis Rheumatol; 2017 Apr; 69(4):763-773. PubMed ID: 27748055 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625 [TBL] [Abstract][Full Text] [Related]